Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide.

Delpassand, Ebrahim S; Samarghandi, Amin; Mourtada, Jennifer Sims; Zamanian, Sara; Espenan, Gregory D; Sharif, Roozbeh; Mackenzie, Shawn; Kosari, Kambiz; Barakat, Omar; Naqvi, Shagufta; Seng, John E; Anthony, Lowell

Delpassand, Ebrahim S; Samarghandi, Amin; Mourtada, Jennifer Sims; Zamanian, Sara; Espenan, Gregory D; Sharif, Roozbeh; Mackenzie, Shawn; Kosari, Kambiz; Barakat, Omar; Naqvi, Shagufta; Seng, John E; Anthony, Lowell.

Afiliação

Delpassand ES; 1. Excel Diagnostics and Nuclear Oncology Center, 9701 Richmond Avenue, suite 122, Houston, Texas, 77042;

Theranostics ; 2(5): 472-80, 2012.

Article em En | MEDLINE | ID: mdl-22737186

Palavras-chave

F-18 FDG PET/CT scan; In-111 Pentetreotide therapy; long term benefits; neuroendocrine tumors; toxicity and survival rate

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2012 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google